Increased lncRNA HOTAIR expression promotes the chemoresistance of multiple myeloma to dexamethasone by
regulating cell viability and apoptosis by mediating the JAK2/STAT3 signaling pathway

Guan,Rongyan; Wang,Wei; Fu,Bin; Pang,Yujun; Lou,Ye; Li,Hong

doi:10.3892/mmr.2019.10603

Increased lncRNA HOTAIR expression promotes the chemoresistance of multiple myeloma to dexamethasone by regulating cell viability and apoptosis by mediating the JAK2/STAT3 signaling pathway

Authors:
- Rongyan Guan
- Wei Wang
- Bin Fu
- Yujun Pang
- Ye Lou
- Hong Li
View Affiliations

Affiliations: Department of Hematology, Daqing Oilfield General Hospital, Daqing, Heilongjiang 163001, P.R. China, Department of Hematology, Heze Municipal Hospital, Heze, Shandong 274000, P.R. China, Department of Central Laboratory, Daqing Oilfield General Hospital, Daqing, Heilongjiang 163001, P.R. China
Published online on: August 22, 2019 https://doi.org/10.3892/mmr.2019.10603
Pages: 3917-3923

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multiple studies have shown that HOX antisense intergenic RNA (HOTAIR), an oncogenic long non‑coding RNA (lncRNA), is dysregulated in leukemia and is involved in tumor progression. The aim of the present study was to determine whether HOTAIR could serve as a novel biomarker for the diagnosis of multiple myeloma (MM), and to investigate its role in regards to MM cell viability and chemoresistance to dexamethasone (DEX). The results revealed that the expression of HOTAIR was significantly upregulated in serum, bone marrow and primary CD138+ cells from MM patients compared with those from normal controls as determined by qPCR. HOTAIR expression was obviously increased in MM cell lines compared to that in normal plasma cells. ROC curve analysis showed that the serum level of HOTAIR exhibited a higher diagnostic value for MM. Furthermore, loss‑of‑functional assays indicated that HOTAIR inhibition suppressed MM cell viability by arresting the cell cycle at the G0/G1 phase as determined by cell viability assay and flow cytometry. An in‑depth study revealed that knockdown of HOTAIR led to decreased chemoresistance of DEX in MM cells by regulating the JAK2/STAT3 signaling pathway. Taken together, our findings suggest that upregulation of serum HOTAIR may prove to be a novel biomarker for the diagnosis of MM. HOTAIR promoted MM cell viability and increased chemoresistance of MM to DEX via the JAK2/STAT3 signaling pathway, indicating HOTAIR may also serve as a potential therapeutic target for MM.

View Figures

View References

1	Spizzo R, Almeida MI, Colombatti A and Calin GA: Long non-coding RNAs and cancer: A new frontier of translational research? Oncogene. 31:4577–4587. 2012. View Article : Google Scholar : PubMed/NCBI
2	Nobili L, Ronchetti D, Agnelli L, Taiana E, Vinci C and Neri A: Long non-coding RNAs in multiple myeloma. Genes (Basel). 9(pii): E692018. View Article : Google Scholar : PubMed/NCBI
3	Wang H, Wang J, Liang CF and Zhou T: Expression of long non-coding RNA PRAL as a potential biomarker for diagnosis in non-small-cell lung cancer patients is associated with the inhibition of cell proliferation and metastasis. Clin Lab. 64:1341–1348. 2018. View Article : Google Scholar : PubMed/NCBI
4	Zhang ZS, Wang J, Zhu BQ and Ge L: Long noncoding RNA UCA1 promotes multiple myeloma cell growth by targeting TGF-β. Eur Rev Med Pharmacol Sci. 22:1374–1379. 2018.PubMed/NCBI
5	Chen L, Hu N, Wang C, Zhao H and Gu Y: Long non-coding RNA CCAT1 promotes multiple myeloma progression by acting as a molecular sponge of miR-181a-5p to modulate HOXA1 expression. Cell Cycle. 17:319–329. 2018. View Article : Google Scholar : PubMed/NCBI
6	Spitzer TR, Sachs DH and Cosimi B: Multiple myeloma. N Engl J Med. 364:23642011. View Article : Google Scholar : PubMed/NCBI
7	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
8	Kuehl WM and Bergsagel PL: Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest. 122:3456–3463. 2012. View Article : Google Scholar : PubMed/NCBI
9	Anderson KC: Progress and paradigms in multiple myeloma. Clin Cancer Res. 22:5419–5427. 2016. View Article : Google Scholar : PubMed/NCBI
10	Robak P, Drozdz I, Szemraj J and Robak T: Drug resistance in multiple myeloma. Cancer Treat Rev. 70:199–208. 2018. View Article : Google Scholar : PubMed/NCBI
11	Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E and Chang HY: Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 129:1311–1323. 2007. View Article : Google Scholar : PubMed/NCBI
12	Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
13	Tang Q and Hann SS: HOTAIR: An oncogenic long non-coding RNA in human cancer. Cell Physiol Biochem. 47:893–913. 2018. View Article : Google Scholar : PubMed/NCBI
14	Xing CY, Hu XQ, Xie FY, Yu ZJ, Li HY, Bin-Zhou, Wu JB, Tang LY and Gao SM: Long non-coding RNA HOTAIR modulates c-KIT expression through sponging miR-193a in acute myeloid leukemia. FEBS Lett. 589:1981–1987. 2015. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Wu Y and Wang H: LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway. J Biochem Mol Toxicol. 32:Jan;2018.doi: 10.1002/jbt.22008. View Article : Google Scholar :
17	Li QY, Chen L, Hu N and Zhao H: Long non-coding RNA FEZF1-AS1 promotes cell growth in multiple myeloma via miR-610/Akt3 axis. Biomed Pharmacother. 103:1727–1732. 2018. View Article : Google Scholar : PubMed/NCBI
18	Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F and Anderson KC: Multiple myeloma. Nat Rev Dis Primers. 3:170462017. View Article : Google Scholar : PubMed/NCBI
19	Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, et al: CD200 is a new prognostic factor in multiple myeloma. Blood. 108:4194–4197. 2006. View Article : Google Scholar : PubMed/NCBI
20	Perosa F, Minoia C, Favoino E, Prete M and Dammacco F: Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count. Blood Cells Mol Dis. 42:71–76. 2009. View Article : Google Scholar : PubMed/NCBI
21	Bhan A, Soleimani M and Mandal SS: Long noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981. 2017. View Article : Google Scholar : PubMed/NCBI
22	Bolha L, Ravnik-Glavač M and Glavač D: Long noncoding RNAs as biomarkers in cancer. Dis Markers. 2017:72439682017. View Article : Google Scholar : PubMed/NCBI
23	Shen X, Zhang Y, Wu X, Guo Y, Shi W, Qi J, Cong H, Wang X, Wu X and Ju S: Upregulated lncRNA-PCAT1 is closely related to clinical diagnosis of multiple myeloma as a predictive biomarker in serum. Cancer Biomark. 18:257–263. 2017. View Article : Google Scholar : PubMed/NCBI
24	Li N, Wang Y, Liu X, Luo P, Jing W, Zhu M and Tu J: Identification of circulating long noncoding RNA HOTAIR as a novel biomarker for diagnosis and monitoring of non-small cell lung cancer. Technol Cancer Res Treat. Jan 1–2017.doi: 10.1177/1533034617723754 (Epub ahead of print). View Article : Google Scholar
25	Elsayed ET, Salem PE, Darwish AM and Fayed HM: Plasma long non-coding RNA HOTAIR as a potential biomarker for gastric cancer. Int J Biol Markers. Apr 1–2018.doi: 10.1177/1724600818760244 (Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
26	Tan SK, Pastori C, Penas C, Komotar RJ, Ivan ME, Wahlestedt C and Ayad NG: Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme. Mol Cancer. 17:742018. View Article : Google Scholar : PubMed/NCBI
27	Wang W, He X, Zheng Z, Ma X, Hu X, Wu D and Wang M: Serum HOTAIR as a novel diagnostic biomarker for esophageal squamous cell carcinoma. Mol Cancer. 16:752017. View Article : Google Scholar : PubMed/NCBI
28	Das M: Lenalidomide plus dexamethasone in multiple myeloma. Lancet Oncol. 19:e122018. View Article : Google Scholar : PubMed/NCBI
29	Zhao JJ, Chu ZB, Hu Y, Lin J, Wang Z, Jiang M, Chen M, Wang X, Kang Y, Zhou Y, et al: Targeting the miR-221-222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance in multiple myeloma. Cancer Res. 75:4384–4397. 2015. View Article : Google Scholar : PubMed/NCBI
30	Arora L, Kumar AP, Arfuso F, Chng WJ and Sethi G: The role of signal transducer and activator of transcription 3 (STAT3) and its targeted inhibition in hematological malignancies. Cancers (Basel). 10(pii): E3272018. View Article : Google Scholar : PubMed/NCBI
31	Liu T, Fei Z, Gangavarapu KJ, Agbenowu S, Bhushan A, Lai JC, Daniels CK and Cao S: Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cells. Leuk Res. 37:1322–1328. 2013. View Article : Google Scholar : PubMed/NCBI
32	Zhu S, Wang Z, Li Z, Peng H, Luo Y, Deng M, Li R, Dai C, Xu Y, Liu S and Zhang G: Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3. Oncotarget. 6:10460–10472. 2015. View Article : Google Scholar : PubMed/NCBI